Plain-English translation of NCT07091799 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers have discovered that a protein called P2X4 on certain immune cells may be involved in ALS, a serious disease that affects nerve cells controlling movement. This trial aims to confirm whether measuring P2X4 levels in blood samples could become a reliable diagnostic tool for ALS. By comparing blood samples from ALS patients and healthy volunteers, the team hopes to prove that this test could help doctors diagnose the disease earlier and more accurately.
Currently, diagnosing ALS is challenging and often takes time because there's no simple blood test for it. If researchers can show that measuring P2X4 is a reliable marker, this could lead to faster, easier diagnosis—which matters because early treatment may help preserve more function and quality of life.
You likely qualify if…
You likely don't qualify if…
If you have ALS, you'll have an initial visit where doctors perform a standard neurological exam, measure your muscle strength and breathing, and take routine blood tests—plus one extra blood sample for the research. You'll return for a follow-up visit six months later for the same exams. If you're a healthy volunteer, you'll complete the initial visit only. The entire process is built into your regular medical appointments, so there's minimal disruption to your normal care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France